Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2025)

Inhibrx Biosciences' (INBX) quarterly Non-Current Debt came in at $100.6 million in Q4 2025, up 0.64% on a QoQ basis from $99.9 million in Q3 2025.

Inhibrx Biosciences (INBX) Non-Current Debt (2023 - 2025) Analysis & Trends

Inhibrx Biosciences (INBX) has 2 years of Non-Current Debt data on file, last reported at $100.6 million in Q4 2025.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $100.6 million in Q4 2025; TTM through Dec 2025 was $100.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $100.6 million, changed N/A from the prior year.
Non-Current Debt for Q4 2025 stood at $100.6 million, up from $99.9 million in the prior quarter.
Over the last five years, Non-Current Debt for INBX reached as high as $207.0 million in Q4 2023 and fell as low as $98.7 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Inhibrx Biosciences	1.32 Bn	1.32 Bn	-	100.56 Mn

Download Data